142 North Cedros Avenue
Solana Beach, CA 92075
858 925 8215
Full Time Employees: 15
|Dr. Stephen T. Worland Ph.D.||CEO, Pres & Director||855.25k||N/A||1958|
|Mr. Michael Byrnes M.B.A.||Chief Financial Officer||623.69k||N/A||1977|
|Dr. Douglas Warner M.D.||Chief Medical Officer||304.4k||N/A||1972|
|Dr. Siegfried Reich Ph.D.||Co-Founder and Member of Clinical & Scientific Advisory Board||N/A||N/A||1960|
|Dr. Davide Ruggero Ph.D.||Co-Founder and Member of Clinical & Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Kevan M. Shokat Ph.D.||Co-Founder and Member of Clinical & Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Mayank J. Gandhi M.D.||Chief Bus. Officer||N/A||N/A||1978|
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
eFFECTOR Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.